Pediatric Drugs

, Volume 15, Issue 1, pp 29–42

Pharmacotherapeutic Management of Pediatric Gliomas

Current and Upcoming Strategies
  • Trent R. Hummel
  • Lionel M. Chow
  • Maryam Fouladi
  • David Franz
Review Article

Abstract

Primary glial brain tumors account for the majority of primary brain tumors in children. They are classified as low-grade gliomas (LGG) or high-grade gliomas (HGG), based on specific pathologic characteristics of the tumor, resulting in disparate clinical prognoses. Surgery is a mainstay of treatment for HGG, although it is not curative, and adjuvant therapy is required. Temozolomide, an oral imidazotetrazine prodrug, while considered standard of care for adult HGG, has not shown the same degree of benefit in the treatment of pediatric HGG. There are significant biologic differences that exist between adult and pediatric HGG, and targets specifically aimed at the biology in the pediatric population are required. Novel and specific therapies currently being investigated for pediatric HGG include small molecule inhibitors of epidermal growth factor receptor, platelet-derived growth factor receptor, histone deacetylase, the RAS/AKT pathway, telomerase, integrin, insulin-like growth factor receptor, and γ-secretase. Surgery is also the mainstay for LGG. There are defined front-line, multiagent chemotherapy regimens, but there are few proven second-line chemotherapy options for refractory patients. Approaches such as the inhibition of the mammalian target of rapamycin pathway, inhibition of MEK1 and 2, as well as BRAF, are discussed. Further research is required to understand the biology of pediatric gliomas as well as the use of molecularly targeted agents, especially in patients with surgically unresectable tumors.

References

  1. 1.
    Altekruse SF, Kosary CL, Krapcho M, et al. editors. SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda (MD) (based on November 2009 SEER data submission, posted to the SEER web site, 2010). http://seer.cancer.gov/csr/1975_2007/. Accessed 8 Nov 2012.
  2. 2.
    Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. February 2011: Hinsdale (IL). http://www.CBTRUS.org. Accessed 8 Nov 2012.
  3. 3.
    Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedGoogle Scholar
  4. 4.
    Bondy ML, et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer. 2008;113(7 suppl):1953–68.PubMedGoogle Scholar
  5. 5.
    Neglia JP, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(21):1528–37.PubMedGoogle Scholar
  6. 6.
    Salvati M, et al. Radio-induced gliomas: 20-year experience and critical review of the pathology. J Neurooncol. 2008;89(2):169–77.PubMedGoogle Scholar
  7. 7.
    Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313–20.PubMedGoogle Scholar
  8. 8.
    Leonard JR, et al. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology. 2006;67(8):1509–12.PubMedGoogle Scholar
  9. 9.
    Guillamo JS, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126(Pt 1):152–60.PubMedGoogle Scholar
  10. 10.
    Melean G, et al. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin Med Genet. 2004;129C(1):74–84.PubMedGoogle Scholar
  11. 11.
    Aydin D, et al. Mobile phone use and brain tumors in children and adolescents: a multicenter case-control study. J Natl Cancer Inst. 2011;103(16):1264–76.PubMedGoogle Scholar
  12. 12.
    Wolff JE, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94(1):264–71.PubMedGoogle Scholar
  13. 13.
    Finlay JL, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol. 1995;13(1):112–23.PubMedGoogle Scholar
  14. 14.
    Kramm CM, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res. 2006;26(5B):3773–9.PubMedGoogle Scholar
  15. 15.
    Sposto R, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165–77.PubMedGoogle Scholar
  16. 16.
    Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical-and futuristic-perspective. J Neurooncol. 2005;75(3):253–66.PubMedGoogle Scholar
  17. 17.
    Fouladi M, et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on children’s cancer group high-grade glioma study CCG-945. Cancer. 2003;98(6):1243–52.PubMedGoogle Scholar
  18. 18.
    Wisoff JH, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the children’s cancer group trial no. CCG-945. J Neurosurg. 1998;89(1):52–9.PubMedGoogle Scholar
  19. 19.
    MacDonald TJ, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of children’s cancer group study 9933. Cancer. 2005;104(12):2862–71.PubMedGoogle Scholar
  20. 20.
    Wolff JE, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol. 2008;87(2):155–64.PubMedGoogle Scholar
  21. 21.
    Wolff JE, et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000;89(10):2131–7.PubMedGoogle Scholar
  22. 22.
    Wolff JE, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79(3):315–21.PubMedGoogle Scholar
  23. 23.
    Wolff JE, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008;90(3):309–14.PubMedGoogle Scholar
  24. 24.
    Wolff JE, et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol. 2011;102(3):433–42.PubMedGoogle Scholar
  25. 25.
    Friedman HS, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995;55(13):2853–7.PubMedGoogle Scholar
  26. 26.
    Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedGoogle Scholar
  27. 27.
    Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.PubMedGoogle Scholar
  28. 28.
    Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedGoogle Scholar
  29. 29.
    Cohen KJ, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13(3):317–23.PubMedGoogle Scholar
  30. 30.
    Broniscer A, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006;76(3):313–9.PubMedGoogle Scholar
  31. 31.
    Cohen KJ, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13(4):410–6.PubMedGoogle Scholar
  32. 32.
    Lashford LS, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20(24):4684–91.PubMedGoogle Scholar
  33. 33.
    Vredenburgh JJ, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.PubMedGoogle Scholar
  34. 34.
    Ali SA, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008;109(2):268–72.PubMedGoogle Scholar
  35. 35.
    Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112(10):2267–73.PubMedGoogle Scholar
  36. 36.
    Gururangan S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol. 2010;28(18):3069–75.PubMedGoogle Scholar
  37. 37.
    Narayana A, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12(9):985–90.PubMedGoogle Scholar
  38. 38.
    Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14(20):6371–5.PubMedGoogle Scholar
  39. 39.
    Gorski DH, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374–8.PubMedGoogle Scholar
  40. 40.
    Lee CG, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565–70.PubMedGoogle Scholar
  41. 41.
    Yuan F, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 1996;93(25):14765–70.PubMedGoogle Scholar
  42. 42.
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.Google Scholar
  43. 43.
    Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.PubMedGoogle Scholar
  44. 44.
    Gallia GL, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006;4(10):709–14.PubMedGoogle Scholar
  45. 45.
    Newcomb EW, et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol. 2000;31(1):115–9.PubMedGoogle Scholar
  46. 46.
    Pollack IF, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61(20):7404–7.PubMedGoogle Scholar
  47. 47.
    Pollack IF, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort. J Neurosurg. 2006;105(5 Suppl.):418–24.PubMedGoogle Scholar
  48. 48.
    Voldborg BR, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8(12):1197–206.PubMedGoogle Scholar
  49. 49.
    Weiss WA. Genetics of brain tumors. Curr Opin Pediatr. 2000;12(6):543–8.PubMedGoogle Scholar
  50. 50.
    Wong KK, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006;66(23):11172–8.PubMedGoogle Scholar
  51. 51.
    Liang ML, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87(3):247–53.PubMedGoogle Scholar
  52. 52.
    Khatua S, et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003;63(8):1865–70.PubMedGoogle Scholar
  53. 53.
    Geoerger B, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.PubMedGoogle Scholar
  54. 54.
    Daw NC, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2005;23(25):6172–80.PubMedGoogle Scholar
  55. 55.
    Bode U, Buchen M, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2006;24(Suppl. 18):1522.Google Scholar
  56. 56.
    Maher EA, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15(11):1311–33.PubMedGoogle Scholar
  57. 57.
    Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2002;2(8):616–26.PubMedGoogle Scholar
  58. 58.
    Holland EC, et al. Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 2004;23(18):3138–44.PubMedGoogle Scholar
  59. 59.
    Holland EC, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25(1):55–7.PubMedGoogle Scholar
  60. 60.
    Faury D, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196–208.PubMedGoogle Scholar
  61. 61.
    Children’s Oncology Group. MK2206 in treating younger patients with recurrent or refractory solid tumors or leukemia [ClinicalTrials.gov identifier NCT01231919]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  62. 62.
    Yoshiji H, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999;59(17):4413–8.PubMedGoogle Scholar
  63. 63.
    Pediatric Brain Tumor Consortium. Enzastaurin in treating young patients with refractory primary CNS tumors [ClinicalTrials.gov identifier NCT00503724]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  64. 64.
    Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335–48.PubMedGoogle Scholar
  65. 65.
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.PubMedGoogle Scholar
  66. 66.
    Geoerger B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61(4):1527–32.PubMedGoogle Scholar
  67. 67.
    Iwamaru A, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007;26(13):1840–51.PubMedGoogle Scholar
  68. 68.
    Geoerger B, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48(2):253–62.PubMedGoogle Scholar
  69. 69.
    Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–18.PubMedGoogle Scholar
  70. 70.
    Naidu KA, et al. Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression. J Neurooncol. 2001;54(1):15–22.PubMedGoogle Scholar
  71. 71.
    Liu TJ, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6(4):1357–67.PubMedGoogle Scholar
  72. 72.
    Andrews DW, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol. 2001;19(8):2189–200.PubMedGoogle Scholar
  73. 73.
    Children’s Oncology Group. Cixutumumab and temsirolimus in treating young patients with solid tumors that have recurred or not responded to treatment [ClinicalTrials.gov identifier NCT00880282]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  74. 74.
    Paugh BS, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–8.PubMedGoogle Scholar
  75. 75.
    Pollack IF, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol. 2007;9(2):145–60.PubMedGoogle Scholar
  76. 76.
    Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.PubMedGoogle Scholar
  77. 77.
    Marks P, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194–202.PubMedGoogle Scholar
  78. 78.
    Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351–6.PubMedGoogle Scholar
  79. 79.
    Weidle UH, Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 2000;20(3A):1471–85.PubMedGoogle Scholar
  80. 80.
    Xu J, et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol. 2011;105(2):241–51.PubMedGoogle Scholar
  81. 81.
    Yin D, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13(3):1045–52.PubMedGoogle Scholar
  82. 82.
    Fouladi M, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623–9.PubMedGoogle Scholar
  83. 83.
    Su JM, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a Children’s Oncology Group report. Clin Cancer Res. 2011;17(3):589–97.PubMedGoogle Scholar
  84. 84.
    Children’s Oncology Group. Vorinostat and radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed pontine glioma [ClinicalTrials.gov identifier NCT01189266]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 1 Sep 2011.
  85. 85.
    Hummel TR, Wagner LM, Ahern CH, et al. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children’s Oncology Group Phase I Consortium Study [abstract no. 9579]. J Clin Oncol 2011; 29Suppl.Google Scholar
  86. 86.
    Greider CW. Telomeres do D-loop-T-loop. Cell. 1999;97(4):419–22.PubMedGoogle Scholar
  87. 87.
    de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948–52.PubMedGoogle Scholar
  88. 88.
    Boldrini L, et al. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006;28(6):1555–60.PubMedGoogle Scholar
  89. 89.
    Huang F, et al. Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol. 1999;43(2):137–42.PubMedGoogle Scholar
  90. 90.
    Maes L, et al. Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep. 2007;18(6):1571–6.PubMedGoogle Scholar
  91. 91.
    Children’s Oncology Group. Imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma [ClinicalTrials.gov identifier NCT01273090]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  92. 92.
    Tabatabai G, et al. Targeting integrins in malignant glioma. Target Oncol. 2010;5(3):175–81.PubMedGoogle Scholar
  93. 93.
    Reardon DA, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008;17(8):1225–35.PubMedGoogle Scholar
  94. 94.
    MacDonald TJ, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol. 2008;26(6):919–24.PubMedGoogle Scholar
  95. 95.
    Lambret CO. Cilengitide in combination with irradiation in children with diffuse intrinsic pontine glioma (CILENT-0902) [ClinicalTrials.gov identifier NCT01165333]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  96. 96.
    Martin-Luther-Universität Halle-Wittenberg. Cilengitide and metronomic temozolomide for relapsed or refractory high grade gliomas or diffuse intrinsic pontine gliomas in children and adolescents (HGG-CilMetro) [ClinicalTrials.gov identifier NCT01517776]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  97. 97.
    Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756–67.PubMedGoogle Scholar
  98. 98.
    Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194(3):237–55.PubMedGoogle Scholar
  99. 99.
    Purow BW, et al. Expression of notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353–63.PubMedGoogle Scholar
  100. 100.
    Fouladi M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011;29(26):3529–34.PubMedGoogle Scholar
  101. 101.
    Children’s Oncology Group. Gamma-secretase inhibitor RO4929097 in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia [ClinicalTrials.gov identifier NCT01088763]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  102. 102.
    Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31.PubMedGoogle Scholar
  103. 103.
    Wu G, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–3.PubMedGoogle Scholar
  104. 104.
    Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009;24(11):1409–17.PubMedGoogle Scholar
  105. 105.
    Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.PubMedGoogle Scholar
  106. 106.
    Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265–71.PubMedGoogle Scholar
  107. 107.
    Mandell LR, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43(5):959–64.PubMedGoogle Scholar
  108. 108.
    Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197–206.PubMedGoogle Scholar
  109. 109.
    Jennings MT, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol. 2002;20(16):3431–7.PubMedGoogle Scholar
  110. 110.
    Korones DN, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227–30.PubMedGoogle Scholar
  111. 111.
    Bouffet E, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000;88(3):685–92.PubMedGoogle Scholar
  112. 112.
    Dunkel IJ, O’Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg. 1996;24(5):263–6.PubMedGoogle Scholar
  113. 113.
    Finlay JL, et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol. 1990;9(3):239–48.PubMedGoogle Scholar
  114. 114.
    Pediatric Brain Tumor Consortium. Capecitabine and radiation therapy in treating young patients with newly diagnosed, nonmetastatic brain stem glioma or high-grade glioma [ClinicalTrials.gov identifier NCT00357253]. US National Institutes of Health, ClinicalTrials. Gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  115. 115.
    Children’s Hospital Medical Center. A study of bevacizumab therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas [ClinialTrials.gov identifier NCT00890786]. US National Institutes of Health [online]. http://clinicaltrials.gov. Accessed 8 Nov 2012.
  116. 116.
    St Jude Children’s Research Hospital. Clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) [ClinicalTrials.gov identifier NCT00996723]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  117. 117.
    National Cancer Institute. Lenalidomide and radiation therapy in high grade gliomas or diffuse intrinsic pontine gliomas [ClinicalTrials.gov identifier NCT01222754]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  118. 118.
    Gilbertson RJ, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9(10 Pt 1):3620–4.PubMedGoogle Scholar
  119. 119.
    Memorial Sloan-Kettering Cancer Center. External beam radiation therapy and cetuximab followed by irinotecan and cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas [ClinicalTrials.gov identifier NCT01012609]. US National Institutes of health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  120. 120.
    Zarghooni M, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44.PubMedGoogle Scholar
  121. 121.
    St Jude Children’s Research Hospital. PDGFR inhibitor crenolanib in children/young adults with diffuse intrinsic pontine glioma or recurrent high-grade glioma [ClinicalTrials.gov identifier NCT01393912]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  122. 122.
    Paugh BS, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006.PubMedGoogle Scholar
  123. 123.
    Monje M, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011;108(11):4453–8.PubMedGoogle Scholar
  124. 124.
    Roujeau T, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007;107(1 Suppl.):1–4.PubMedGoogle Scholar
  125. 125.
    Grill J, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012;58(4):489–91.PubMedGoogle Scholar
  126. 126.
    Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397–408.PubMedGoogle Scholar
  127. 127.
    Freeman CR, Farmer JP, Montes J. Low-grade astrocytomas in children: evolving management strategies. Int J Radiat Oncol Biol Phys. 1998;41(5):979–87.PubMedGoogle Scholar
  128. 128.
    Pollack IF. The role of surgery in pediatric gliomas. J Neurooncol. 1999;42(3):271–88.PubMedGoogle Scholar
  129. 129.
    Desai KI, et al. Prognostic factors for cerebellar astrocytomas in children: a study of 102 cases. Pediatr Neurosurg. 2001;35(6):311–7.PubMedGoogle Scholar
  130. 130.
    Fisher PG, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer. 2008;51(2):245–50.PubMedGoogle Scholar
  131. 131.
    Pollack IF, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg. 1995;82(4):536–47.PubMedGoogle Scholar
  132. 132.
    Grabenbauer GG, et al. Radiation therapy of optico-hypothalamic gliomas (OHG): radiographic response, vision and late toxicity. Radiother Oncol. 2000;54(3):239–45.PubMedGoogle Scholar
  133. 133.
    Karim AB, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549–56.PubMedGoogle Scholar
  134. 134.
    Kortmann RD, et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: treatment modalities of radiation therapy. Strahlenther Onkol. 2003;179(8):509–20.PubMedGoogle Scholar
  135. 135.
    Laws ER Jr, et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61(4):665–73.PubMedGoogle Scholar
  136. 136.
    Shibamoto Y, et al. Supratentorial low-grade astrocytoma: correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 1993;72(1):190–5.PubMedGoogle Scholar
  137. 137.
    Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery. 1991;28(4):496–501.PubMedGoogle Scholar
  138. 138.
    McCormack BM, et al. Treatment and survival of low-grade astrocytoma in adults: 1977–1988. Neurosurgery. 1992;31(4):636–42. (discussion 642).PubMedGoogle Scholar
  139. 139.
    Broniscer A, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;25(6):682–9.PubMedGoogle Scholar
  140. 140.
    Packer RJ, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–54.PubMedGoogle Scholar
  141. 141.
    Lafay-Cousin L, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer. 2008;112(4):892–9.PubMedGoogle Scholar
  142. 142.
    Yu DY, et al. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol. 2001;23(6):349–52.PubMedGoogle Scholar
  143. 143.
    Prados MD, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32(3):235–41.PubMedGoogle Scholar
  144. 144.
    Ater J, Holmes E, Zhou T, et al. Abstracts from the thirteenth international symposium on pediatric neuro-oncology: results of COG protocol A9952: a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 2008;10:451.Google Scholar
  145. 145.
    Massimino M, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209–16.PubMedGoogle Scholar
  146. 146.
    Lafay-Cousin L, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103(12):2636–42.PubMedGoogle Scholar
  147. 147.
    Gururangan S, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9(2):161–8.PubMedGoogle Scholar
  148. 148.
    Khaw SL, et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49(6):808–11.PubMedGoogle Scholar
  149. 149.
    Nicholson HS, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer. 2007;110(7):1542–50.PubMedGoogle Scholar
  150. 150.
    Packer RJ, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791–5.PubMedGoogle Scholar
  151. 151.
    Orr LC, et al. Cytogenetics in pediatric low-grade astrocytomas. Med Pediatr Oncol. 2002;38(3):173–7.PubMedGoogle Scholar
  152. 152.
    White FV, et al. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol. 1995;26(9):979–86.PubMedGoogle Scholar
  153. 153.
    Bar EE, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878–87.PubMedGoogle Scholar
  154. 154.
    Jones DT, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–7.PubMedGoogle Scholar
  155. 155.
    Sievert AJ, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449–58.PubMedGoogle Scholar
  156. 156.
    Pediatric Brain Tumor Consortium. MEK inhibitor AZD6244 in treating young patients with recurrent or refractory low grade glioma [ClinicalTrials.gov identifier NCT01089101]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  157. 157.
    New York University School of Medicine. Sorafenib in children and young adults with recurrent or progressive low-grade astrocytomas [ClinicalTrials.gov identifier NCT01338857]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
  158. 158.
    Dowling RJ, et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804(3):433–9.PubMedGoogle Scholar
  159. 159.
    Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005;14 Spec No. 2:R251–8.PubMedGoogle Scholar
  160. 160.
    Napolioni V, Curatolo P. Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics. 2008;9(7):475–87.PubMedGoogle Scholar
  161. 161.
    Inoki K, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–57.PubMedGoogle Scholar
  162. 162.
    Orlova KA, Crino PB. The tuberous sclerosis complex. Ann NY Acad Sci. 2010;1184:87–105.PubMedGoogle Scholar
  163. 163.
    Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56.PubMedGoogle Scholar
  164. 164.
    Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23(10):1238–9.PubMedGoogle Scholar
  165. 165.
    Birca A, Mercier C, Major P. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr. 2010;6(4):381–4.PubMedGoogle Scholar
  166. 166.
    Franz DN, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490–8.PubMedGoogle Scholar
  167. 167.
    Lam C, et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 2010;54(3):476–9.PubMedGoogle Scholar
  168. 168.
    Krueger DA, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–11.PubMedGoogle Scholar
  169. 169.
    Gutmann DH. Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol. 2008;23(10):1186–94.PubMedGoogle Scholar
  170. 170.
    Listernick R, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41(2):143–9.PubMedGoogle Scholar
  171. 171.
    Dasgupta B, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65(7):2755–60.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  • Trent R. Hummel
    • 1
  • Lionel M. Chow
    • 1
  • Maryam Fouladi
    • 1
  • David Franz
    • 2
  1. 1.Division of Oncology, Cancer and Blood Diseases InstituteCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  2. 2.Department of NeurologyCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations